PPARG and metabolic dysfunction-associated steatotic liver disease: This study demonstrated that lncRNA-Snhg3 participated in the pathology of MASLD by epigenetic modification; that is, Snhg3 inhibited the H3K27me3 level, and promoted chromatin relaxation at the Pparg promoter and eventually increased PPARγ expression.